Vladimir Vexler
Equibles does not estimate personal net worth.
Get an email with a short summary when Coherus Oncology, Inc. publishes a filing, an earnings call transcript or a press release.
Get CHRS alertsAbout Vladimir Vexler
The proxy statement of Coherus Oncology, Inc. reports total compensation of $1,757,229 for Vladimir Vexler in fiscal 2019, including a base salary of $447,525. Disclosed compensation is on record for 2 fiscal years. Coherus Oncology, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Coherus Oncology, Inc. includes Dennis Lanfear (CEO), Bryan McMichael (CFO and Chief Accounting Officer), Alan C. Mendelson (Board Member) and 7 others.
Affiliation history
-
Coherus Oncology, Inc. (CHRS)
Proxy statement
CurrentStart not stated–present
Last confirmed April 17, 2023
Company network
Leadership on record at Coherus Oncology, Inc.
- Dennis Lanfear CEO
- Bryan McMichael CFO, Chief Accounting Officer
- Alan C. Mendelson Board Member
- Charles Newton Board Member
- Georgia Erbez Board Member
- Jill O'Donnell-Tormey, Ph.D. Board Member
- Lee N. Newcomer Board Member
- Mark D. Stolper Board Member
- Michael Ryan Board Member
- Rita A. Karachun Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2019 | Coherus Oncology, Inc. (CHRS) | Chief Scientific Officer | $447,525 | $1,757,229 |
| 2018 | Coherus Oncology, Inc. (CHRS) | Chief Scientific Officer | $393,083 | $1,355,163 |
Recent activity
No call appearances or filed executive changes recorded yet.